Zoetis Inc. $ZTS Shares Sold by 180 Wealth Advisors LLC

180 Wealth Advisors LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 3.3% during the second quarter, HoldingsChannel.com reports. The fund owned 3,593 shares of the company’s stock after selling 124 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Zoetis were worth $560,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ZTS. Nuveen LLC acquired a new stake in shares of Zoetis in the 1st quarter worth approximately $616,375,000. Mackenzie Financial Corp lifted its stake in Zoetis by 4,158.3% in the 1st quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock valued at $300,481,000 after buying an additional 1,782,110 shares in the last quarter. Polen Capital Management LLC lifted its stake in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Amundi lifted its stake in Zoetis by 30.8% in the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after buying an additional 846,909 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its stake in Zoetis by 475.9% in the 1st quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 900,261 shares of the company’s stock valued at $148,228,000 after buying an additional 743,926 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $146.14 on Friday. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $184.40. The stock’s fifty day simple moving average is $148.18 and its 200-day simple moving average is $153.50. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market capitalization of $64.77 billion, a price-to-earnings ratio of 25.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Piper Sandler upped their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, UBS Group reduced their price target on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research note on Monday. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.